絞り込み

16640

広告

ダビンチ没後500年記念 最大規模の特別展 仏ルーブル美術館

ルネサンスの巨匠、レオナルド・ダビンチの没後500年を記念して、世界中からダビンチやその弟子たちの作品を集めた過去最大規模の特別展が、24日からフランスのルーブ...

  1. [企業] Provention Bio社...
  2. クルド人はどんな人たち? 4カ国に暮らす...
  3. インフルエンザ新防御機構を東大が解明、効...
  4. ニホンザル 餌を得るため2匹が協力 初め...

ニュース一覧

Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle.

著者 Sardi SP , Cheng SH , Shihabuddin LS
Prog Neurobiol.2015 Jan 6 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (157view , 0users)

Full Text Sources

Medical

Other Literature Sources

Gaucher disease, the most common lysosomal storage disease, is caused by a recessively inherited deficiency in glucocerebrosidase and subsequent accumulation of toxic lipid substrates. Heterozygous mutations in the lysosomal glucocerebrosidase gene (GBA1) have recently been recognized as the highest genetic risk factor for the development of α-synuclein aggregation disorders ("synucleinopathies"), including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Despite the wealth of experimental, clinical and genetic evidence that supports the association between mutant genotypes and synucleinopathy risk, the precise mechanisms by which GBA1 mutations lead to PD and DLB remain unclear. Decreased glucocerebrosidase activity has been demonstrated to promote α-synuclein misprocessing. Furthermore, aberrant α-synuclein species have been reported to downregulate glucocerebrosidase activity, which further contributes to disease progression. In this review, we summarize the recent findings that highlight the complexity of this pathogenetic link and how several pathways that connect glucocerebrosidase insufficiency with α-synuclein misprocessing have emerged as potential therapeutic targets. From a translational perspective, we discuss how various therapeutic approaches to lysosomal dysfunction have been explored for the treatment of GBA1-related synucleinopathies, and potentially, for non-GBA1-associated neurodegenerative diseases. In summary, the link between GBA1 and synucleinopathies has become the paradigm of how the study of a rare lysosomal disease can transform the understanding of the etiopathology, and hopefully the treatment, of a more prevalent and multifactorial disorder.
PMID: 25573151 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード